These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19797536)

  • 1. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects.
    Nunes T; Almeida L; Rocha JF; Falcão A; Fernandes-Lopes C; Loureiro AI; Wright L; Vaz-da-Silva M; Soares-da-Silva P
    J Clin Pharmacol; 2009 Dec; 49(12):1477-82. PubMed ID: 19797536
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers.
    Almeida L; Vaz-da-Silva M; Falcão A; Soares E; Costa R; Loureiro AI; Fernandes-Lopes C; Rocha JF; Nunes T; Wright L; Soares-da-Silva P
    Mol Nutr Food Res; 2009 May; 53 Suppl 1():S7-15. PubMed ID: 19194969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease.
    Nagayama H; Ueda M; Kumagai T; Tsukamoto K; Nishiyama Y; Nishimura S; Hamamoto M; Katayama Y
    Parkinsonism Relat Disord; 2011 Mar; 17(3):150-2. PubMed ID: 21172738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease.
    Nyholm D; Lennernäs H; Johansson A; Estrada M; Aquilonius SM
    Clin Neuropharmacol; 2010 Jul; 33(4):181-5. PubMed ID: 20661024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects.
    la Porte C; Voduc N; Zhang G; Seguin I; Tardiff D; Singhal N; Cameron DW
    Clin Pharmacokinet; 2010 Jul; 49(7):449-54. PubMed ID: 20528005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of resveratrol derivatives in humans after oral administration of melinjo (Gnetum gnemon L.) seed extract powder.
    Tani H; Hikami S; Iizuna S; Yoshimatsu M; Asama T; Ota H; Kimura Y; Tatefuji T; Hashimoto K; Higaki K
    J Agric Food Chem; 2014 Feb; 62(8):1999-2007. PubMed ID: 24495149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is levodopa toxic to human substantia nigra?
    Riley D
    Mov Disord; 1998 Mar; 13(2):369-70. PubMed ID: 9539360
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
    Deleu D; Jacob P; Chand P; Sarre S; Colwell A
    Neurology; 2006 Sep; 67(5):897-9. PubMed ID: 16966563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion.
    Westin J; Nyholm D; Pålhagen S; Willows T; Groth T; Dougherty M; Karlsson MO
    Clin Neuropharmacol; 2011; 34(2):61-5. PubMed ID: 21297456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
    Keller GA; Czerniuk P; Bertuola R; Spatz JG; Assefi AR; Di Girolamo G
    Clin Ther; 2011 Apr; 33(4):500-10. PubMed ID: 21635995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa.
    Goole J; Van Gansbeke B; Pilcer G; Deleuze P; Blocklet D; Goldman S; Pandolfo M; Vanderbist F; Amighi K
    Int J Pharm; 2008 Nov; 364(1):54-63. PubMed ID: 18778758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of continuous-release carbidopa/levodopa.
    Sage JI; Mark MH
    Clin Neuropharmacol; 1994; 17 Suppl 2():S1-6. PubMed ID: 9358189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.
    Muhlack S; Woitalla D; Welnic J; Twiehaus S; Przuntek H; Müller T
    Neurosci Lett; 2004 Jun; 363(3):284-7. PubMed ID: 15182961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.
    Vetrugno R; Contin M; Baruzzi A; Provini F; Plazzi G; Montagna P
    Mov Disord; 2006 Feb; 21(2):254-8. PubMed ID: 16200540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New use for an old drug: amantadine benefits levodopa-induced dyskinesia.
    Rajput AH; Rajput A; Lang AE; Kumar R; Uitti RJ; Galvez-Jimenez N
    Mov Disord; 1998 Sep; 13(5):851. PubMed ID: 9756161
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioavailability of trans-resveratrol from red wine in humans.
    Vitaglione P; Sforza S; Galaverna G; Ghidini C; Caporaso N; Vescovi PP; Fogliano V; Marchelli R
    Mol Nutr Food Res; 2005 May; 49(5):495-504. PubMed ID: 15830336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.